The phase III randomised controlled, double‐blinded PACIFIC trial compared durvalumab (anti‐PD‐L1) to placebo in patients with stage III NSCLC who were progression‐free after receiving two or many cycles of platinum‐based chemoradiotherapy, increasing the median PFS from 5.6 to 16.8 months with the addition of durvalumab. Here, CD274 is linked to non-small cell lung carcinoma.